<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diabetic kidney disease: Pathogenesis and epidemiology</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diabetic kidney disease: Pathogenesis and epidemiology</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diabetic kidney disease: Pathogenesis and epidemiology</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy K Mottl, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katherine R Tuttle, MD, FASN, FACP, FNKF</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H942722043"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Diabetes is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in the United States and worldwide. Diabetic kidney disease is a complex and heterogeneous disease with numerous overlapping etiologic pathways including changes in glomerular hemodynamics, oxidative stress and inflammation, and interstitial fibrosis and tubular atrophy.</p><p>The pathogenesis and epidemiology of diabetic kidney disease are reviewed here. Other topics discuss the following issues:</p><p class="bulletIndent1"><span class="glyph">●</span>Manifestations, evaluation, and diagnosis of diabetic kidney disease (see  <a class="medical medical_review" href="/d/html/119881.html" rel="external">"Diabetic kidney disease: Manifestations, evaluation, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of diabetic kidney disease (see  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of hypertension in patients with diabetes (see  <a class="medical medical_review" href="/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>)</p><p></p><p class="headingAnchor" id="H3833541823"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Diabetic kidney disease is a complex and heterogeneous disease with numerous overlapping etiologic pathways [<a href="#rid1">1</a>]. Hyperglycemia results in production of advanced glycation end-products (AGE) and reactive oxygen species. These aberrant metabolic products activate intercellular signaling for proinflammatory and profibrotic gene expression with production of a host of mediators for cellular injury [<a href="#rid2">2,3</a>]. While hyperglycemia undoubtedly plays a central role, hyperinsulinemia, insulin resistance, and lipotoxicity also may incite pathogenic mechanisms, possibly accounting for variation in histopathology between type 1 and type 2 diabetes [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/119881.html" rel="external">"Diabetic kidney disease: Manifestations, evaluation, and diagnosis", section on 'Manifestations and diagnosis'</a> and  <a class="medical medical_review" href="/d/html/119881.html" rel="external">"Diabetic kidney disease: Manifestations, evaluation, and diagnosis", section on 'Natural history'</a>.)</p><p>Ultimately, alterations in glomerular hemodynamics, inflammation, and fibrosis are primary mediators of kidney tissue damage, although the relative contribution of these mechanisms likely varies between individuals and over the course of the natural history of diabetic kidney disease.</p><p class="headingAnchor" id="H3455502924"><span class="h2">Glomerular hemodynamics</span><span class="headingEndMark"> — </span>The diabetic milieu activates the renin-angiotensin-aldosterone system (RAAS) and numerous other downstream mediators, triggering kidney hypertrophy, increased renal plasma flow (RPF), and increased filtration fraction (FF), which together result in an abnormally elevated glomerular filtration rate (GFR)  (<a class="graphic graphic_figure graphicRef122590" href="/d/graphic/122590.html" rel="external">figure 1</a>) [<a href="#rid5">5</a>]. In the early stages of diabetes, "whole kidney GFR" and "single nephron GFR (SNGFR)" are increased. These states are often referred to as "glomerular hyperfiltration [<a href="#rid6">6,7</a>]." (See <a class="local">'Glomerular hyperfiltration'</a> below.)</p><p>While increased RPF and FF are partly due to an increase in kidney size, they are predominantly the result of disproportionately reduced afferent versus efferent arteriolar resistance [<a href="#rid8">8</a>]. Increased circulating and local vasodilators, such as atrial natriuretic peptide, nitric oxide, and prostanoids, and a relative deficiency or resistance to insulin have a preferential impact on reducing afferent arteriole resistance [<a href="#rid6">6,7</a>]. By contrast, an increase in circulating and local vasoconstrictors, including angiotensin II, thromboxane and endothelin 1, have a greater effect to increase efferent arteriole resistance. The imbalance in tone between afferent and efferent arterioles increases intraglomerular pressure that, over time, triggers a sclerotic response in diabetic kidney disease [<a href="#rid5">5</a>].</p><p>Tubular function also has an impact on glomerular hemodynamics, via tubuloglomerular feedback [<a href="#rid1">1</a>]. Diabetes is associated with a decrease in sodium, chloride, and solute delivery to the macula densa. This occurs early in the course of diabetes as the proximal tubule hypertrophies and there is upregulation of the sodium-glucose cotransporters (SGLT1 and SGLT2). Reabsorption of glucose, sodium, and chloride is increased in relatively moderate hyperglycemia (&gt;180 mg/dL), resulting in decreased solute delivery to the macula densa portion of the distal tubule. Consequently, afferent arteriolar tone is reduced, thereby producing increases in RPF, FF, and GFR. The impact of tubular function on progression of diabetic kidney disease is further underscored by findings that inhibition of SGLT2 results in an initial, short-term decline in estimated GFR (eGFR) but a long-term delay in kidney disease progression [<a href="#rid9">9-11</a>]. This effect is presumably due, sequentially, to decreased reabsorption of sodium and chloride along with glucose in the proximal tubule, thereby increasing distal delivery of solutes to the macula densa, restoration of tubuloglomerular feedback, and a reduction in glomerular hyperfiltration [<a href="#rid12">12</a>]. The initial decrease in eGFR after SGLT2 inhibition also occurs in those with low eGFR, and, ultimately, the rate of eGFR decline is slowed over time regardless of eGFR at initiation [<a href="#rid13">13-16</a>].</p><p>Further exacerbation of glomerular hyperfiltration also occurs in diabetes due to impaired autoregulatory responses of the afferent arterioles to fluctuations in blood pressure [<a href="#rid17">17</a>]. Thus, increases in blood pressure, which would result in protective increases in vascular tone under normal physiological circumstances, are transmitted along to glomerular capillaries in diabetes.</p><p>These anomalous vascular changes result in increased intraglomerular pressure and SNGFR, causing physical stress to capillary walls, podocytes, and mesangium, ultimately triggering a profibrotic response. As glomeruli become sclerosed and whole kidney GFR decreases, RPF is shunted to the remaining viable glomeruli, causing further increases in SNGFR of the less damaged glomeruli. Numerous studies in type 1 and type 2 diabetes have subsequently demonstrated an association between elevated eGFR and worsening albuminuria [<a href="#rid6">6</a>], although a direct link between hyperfiltration and worsening albuminuria is more difficult to demonstrate, in part due to the long duration of follow-up that is required to observe such changes. (See <a class="local">'Glomerular hyperfiltration'</a> below.)</p><p class="headingAnchor" id="H124135484"><span class="h3">Glomerular hyperfiltration</span><span class="headingEndMark"> — </span>Hyperfiltration can be defined at the level of the single nephron, wherein the ratio between GFR and effective RPF (ie, FF) is elevated due to either altered glomerular hemodynamics or glomerular damage with hypertrophy of remnant nephrons [<a href="#rid6">6,7,18</a>]. FF is difficult to measure in humans, and most studies of glomerular hyperfiltration have focused on "supraphysiologic" whole kidney GFR, generally defined as greater than two standard deviations above normal. Thus, glomerular hyperfiltration is usually defined between 120 and 140 mL/min/1.73 m<sup>2</sup>, depending on age [<a href="#rid6">6</a>]. There are shortcomings to ascribing a particular GFR cut point for hyperfiltration, including GFR differences by sex and age [<a href="#rid19">19,20</a>], but also variability in glomerular endowment, which can differ by nearly 10-fold [<a href="#rid19">19,21</a>]. Moreover, there is also significant intraindividual variability in GFR [<a href="#rid22">22</a>], which can be affected by transient physiologic states including hyperglycemia and hyperaminoacidemia, such as occurs after protein feeding [<a href="#rid23">23-25</a>].</p><p>The prevalence of glomerular hyperfiltration depends partly on the duration of diabetes. Among cohorts with at least 100 participants with type 1 diabetes of less than 10 years duration and measured GFR, the prevalence of hyperfiltration ranges between 34 and 67 percent [<a href="#rid6">6</a>]. Duration of diabetes is more difficult to assess and is generally not provided in studies of type 2 diabetes cohorts; however, prevalence of hyperfiltration in larger cohorts (n≥100) with measured GFR ranges between 6 and 23 percent [<a href="#rid6">6</a>]. Reasons for the lower prevalence of hyperfiltration in type 2 versus type 1 diabetes may include older age and resultant glomerulosclerosis from hypertension and/or age-related senescence of the kidney.</p><p>Numerous studies have probed the association between glomerular hyperfiltration and worsening albuminuria, with most demonstrating a positive association [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 10 studies of patients with type 1 diabetes and measured GFR found that hyperfiltration was associated with a higher risk of moderately or severely increased albuminuria at 11 years (odds ratio 2.7, 95 percent CI 1.2-6.1) [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a post-hoc analysis of 600 clinical trial participants with type 2 diabetes and repeated measures of GFR before and after initiation of an angiotensin converting enzyme (ACE) inhibitor found that, of the participants with baseline hyperfiltration, only those with persistent hyperfiltration after ACE inhibitor initiation were at increased risk for developing albuminuria [<a href="#rid27">27</a>]. In addition, the annual rate of GFR decline in those with baseline hyperfiltration that was normalized by ACE inhibitor use was slower than in those patients who had had persistent hyperfiltration despite taking ACE inhibitors (2.4 versus 5.2 mL/min/1.73 m<sup>2</sup>).</p><p></p><p>Few studies have examined the association of glomerular hyperfiltration with eGFR decline, and none included endpoints such as end-stage kidney disease (ESKD) or death attributed to kidney disease. As an example, in a study of 646 patients with type 1 diabetes followed for six years, baseline hyperfiltration (defined as eGFR ≥120 mL/min/1.73 m<sup>2</sup>) was associated with both rapid eGFR decline, defined as loss of ≥3 mL/min/1.73m<sup>2</sup> per year (odds ratio 5.0, 95% CI 3.0-8.3) and the incidence of an eGFR &lt;60 mL/min/1.73 m<sup>2</sup> (odds ratio 16.0, 95% CI 2.3-114) [<a href="#rid28">28</a>].</p><p>These data support the hypothesis that normalization of whole kidney hyperfiltration may slow the rate of chronic kidney disease (CKD) progression. This is considered to be one of the primary mechanisms by which ACE inhibitors and angiotensin receptor blockers (ARBs) mitigate kidney disease, as they preferentially decrease arteriolar resistance in the efferent compared with afferent arteriole, thereby lowering glomerular pressure [<a href="#rid29">29</a>]. Complementary physiologic effects of SGLT2 inhibitors may explain why this class of antihyperglycemic agents is also protective for diabetic kidney disease [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a>.)</p><p class="headingAnchor" id="H895010525"><span class="h2">Innate immunity, oxidative stress, and inflammation</span><span class="headingEndMark"> — </span>Innate immunity is an increasingly recognized contributor to the pathogenesis of diabetic kidney disease. Integral to the innate immunity are oxidative stress and inflammation  (<a class="graphic graphic_figure graphicRef132710" href="/d/graphic/132710.html" rel="external">figure 2</a>). Hyperglycemia as well as insulin resistance and dyslipidemia cause increased formation of AGE, which, upon binding to AGE receptors (RAGE) located on multiple cell types in the kidney, induces production of numerous cytokines (tumor necrosis factor [TNF], interleukin 6 (IL-6), IL-1beta) via activation of nuclear transcription factors, such as NF-kappaB [<a href="#rid31">31,32</a>]. A similar signaling pathway occurs via stimulation of toll-like receptors by exposure to hyperglycemia and damaged cellular components (as occurs with oxidative stress). Oxidative stress and inflammation are tightly intertwined, creating a vicious cycle wherein one process begets the other via multiple mediators [<a href="#rid3">3,33,34</a>].</p><p>Macrophage infiltration is a hallmark of diabetic kidney disease, the magnitude of which correlates with worsening disease [<a href="#rid35">35,36</a>]. Macrophages can be recruited and activated by hyperglycemic stress, angiotensin II, oxidized low-density lipoproteins, AGE, and kidney injury molecule 1 [<a href="#rid37">37</a>]. The result is increased oxidative stress and production of injurious cytokines including transforming growth factor (TGF)-beta and platelet derived growth factor. Macrophages are also a rich source of TNF-alpha, a pleiotropic cytokine resulting in kidney hypertrophy, podocyte and tubular epithelial cell injury, and the triggering of a cascade of other cytokines [<a href="#rid36">36,38</a>].</p><p>Hyperglycemia also results in increased shunting of glucose through non-glycolytic pathways such as the polyol pathway, which increases oxidative stress. Protein kinase C (PKC) is also activated by a hyperglycemic environment, resulting in decreased production of endothelial nitric oxide synthase (eNOS) and increased levels of the endothelin 1 and vascular endothelial growth factor (VEGF), which promotes endothelial instability and NF-kappaB stimulated cytokine production.</p><p>Mesangial cell hypertrophy and matrix accumulation, hallmarks of diabetic glomerulosclerosis, are mediated by the transforming growth factor-beta (TGF-beta) system [<a href="#rid39">39,40</a>]. TGF-beta production by the mesangial cell is activated by a hyperglycemic environment and angiotensin II and has been found to not only trigger glomerular extracellular mesangial matrix production but also to decrease the production of matrix metalloproteinases, which are responsible for keeping extracellular matrix in check through degradation [<a href="#rid39">39</a>]. A primary mediator of TGF-beta on mesangial expansion is connective tissue growth factor (CTGF); however, CTGF can also be directly stimulated by hyperglycemia, mechanical strain, and AGE [<a href="#rid41">41</a>].</p><p>Vascular proliferation and endothelial permeability are increased in diabetic kidney disease and are thought to be mediated by VEGF [<a href="#rid42">42</a>], particularly when accompanied by diabetes-induced downregulation of endothelial nitric oxide production [<a href="#rid43">43</a>]. Angiopoietins (ANGPT) are also important regulators of endothelial function, necessitating a balance between ANGPT1, which stabilizes the endothelium, and ANGPT2, which promotes endothelial proliferation [<a href="#rid44">44</a>]. The ratio of ANGPT2 to ANGPT1 is consistently elevated in both experimental models of diabetic kidney disease as well as from tissue specimens from human diabetic glomerulopathy.</p><p class="headingAnchor" id="H1731879716"><span class="h2">Interstitial fibrosis and tubular atrophy (IFTA)</span><span class="headingEndMark"> — </span>As diabetic kidney disease progresses, there is a clear relationship between the degree of interstitial fibrosis/tubular atrophy (IFTA) and decline in eGFR [<a href="#rid45">45</a>]. Hyperglycemia results in shunting of glucose through the hexosamine pathway and subsequently increased production of TGF-beta and plasminogen activator inhibitor 1 (PAI-1) [<a href="#rid46">46</a>]. Damage to the proximal tubular cell from AGE, angiotensin II, and albuminuria also results in increased TGF-beta with consequent conversion of pericytes into myofibroblasts (epithelial to mesenchymal transformation), infiltration of macrophages, and an excess of collagen and fibronectin deposition [<a href="#rid1">1,47</a>].</p><p class="headingAnchor" id="H3443866769"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span></p><p class="headingAnchor" id="H1775823769"><span class="h2">Incidence and prevalence</span><span class="headingEndMark"> — </span>Diabetes is the leading ascribed cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in the United States [<a href="#rid48">48</a>] and worldwide [<a href="#rid49">49</a>]. However, the true incidence and prevalence of diabetic kidney disease, CKD attributable to diabetes per se, is not clear, because kidney biopsies (the gold standard for diagnosis of diabetic kidney disease) are infrequently performed in patients with diabetes and CKD.</p><p>Nevertheless, the overall burden of diabetic kidney disease is high, resulting in decreased quality of life and increased rates of disability and premature death [<a href="#rid50">50</a>]. Globally, the age-standardized incidence of diabetic kidney disease decreased by approximately 10 percent from 1990 to 2017; however, disability-adjusted life years and mortality increased over this period (by approximately 20 percent and 10 percent, respectively) [<a href="#rid51">51</a>]. Health care costs are also significantly increased in people with diabetic kidney disease [<a href="#rid52">52</a>].</p><p>Although the prevalence of diabetes in the United States has risen over the last 20 years from 6 to 11 percent, the proportion of people with diabetes who also have CKD has remained relatively stable (approximately 25 to 30 percent) [<a href="#rid53">53</a>]. However, the distribution of clinical manifestations of diabetic kidney disease has changed over time. (see  <a class="medical medical_review" href="/d/html/119881.html" rel="external">"Diabetic kidney disease: Manifestations, evaluation, and diagnosis"</a>) [<a href="#rid53">53</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of persistent moderately to severely increased albuminuria (ie, a urine albumin-to-creatinine ratio ≥30 mg/g) in patients with diabetes decreased from approximately 20 percent during the period from 1988 to 1994 to approximately 15 percent during the period from 2009 to 2014.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, the prevalence of decreased estimated glomerular filtration rate (eGFR), defined as an eGFR &lt;60 mL/min/1.73 m<sup>2</sup>, increased from approximately 10 to 15 percent.</p><p></p><p>Despite the high prevalence of kidney disease among people with diabetes, CKD awareness is extremely low in the United States. Only 10 percent of people with stage 3 CKD (eGFR 30 to 59 mL/min/1.73 m<sup>2</sup>) are aware of their diagnosis; although this proportion is higher among people with stage 4 CKD (eGFR 15 to 29 mL/min/1.73 m<sup>2</sup>), less than 60 percent of patients overall are aware of their disease [<a href="#rid48">48,54,55</a>].</p><p>The prevalence of ESKD more than doubled from 2000 to 2019 to nearly 800,000 people, primarily driven by diabetes [<a href="#rid56">56</a>]. As of 2019, more than 307,000 people in the United States had ESKD primarily attributed to diabetes, accounting for nearly 40 percent of all patients with ESKD [<a href="#rid56">56</a>]. However, most people with diabetes and CKD die before requiring kidney replacement therapy [<a href="#rid57">57-59</a>]. </p><p>Worldwide, the annual incidence of ESKD attributed to diabetes is rising [<a href="#rid60">60</a>]. The incidence is increasing fastest in the African and Western Pacific regions and among lower-income groups. These data underscore the growing toll of diabetes on health and its disproportionate impact in underserved populations.</p><p class="headingAnchor" id="H1401717564"><span class="h3">Type 1 versus type 2 diabetes</span><span class="headingEndMark"> — </span>It is unclear whether the natural history and rate of progression of diabetic kidney disease differs according to diabetes type. In the vast majority of people with type 2 diabetes, disease onset is after the age of 40 years, and other factors such as age-related senescence of the kidney and hypertension can contribute to kidney function decline to varying degrees. In addition, type 2 diabetes can be asymptomatic for years, resulting in a delay in diagnosis; therefore, the true time of onset of the hyperglycemic exposure is usually unknown.</p><p>Few studies have directly compared rates of diabetic kidney disease according to diabetes type; in general, rates of albuminuria seem to be similar, but decreased eGFR is more common in patients with type 2 diabetes. A systematic review of studies with type 1 or type 2 diabetes and kidney disease found slightly higher annualized incidence rates of albuminuria among cohorts of type 2 (3.8 to 12.7 percent per year) compared with type 1 diabetes (1.3 to 3.8 percent per year) [<a href="#rid61">61</a>]. However, diabetes duration varied between the studies, potentially confounding the findings. A large population-based study in the United Kingdom found that, among those with preserved eGFR (≥60 mL/min/1.73 m<sup>2</sup>), the prevalence of increased albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g) was similar (18 percent) in patients with type 1 and type 2 diabetes [<a href="#rid62">62</a>]. By contrast, the prevalence of decreased eGFR (&lt;60 mL/min/1.73 m<sup>2</sup>) was less common in type 1 (14 percent) than in type 2 diabetes (25 percent).</p><p>The incidence of ESKD is variable and it is unknown if the rate differs according to diabetes type [<a href="#rid63">63-65</a>]. As an example, in one study of people with diabetes and albuminuria at baseline, the unadjusted incidence rates of ESKD were 18 and 47 cases per 1000 person-years in those with type 1 and type 2 diabetes, respectively [<a href="#rid64">64</a>]. Unadjusted mortality rates were also higher among patients with type 2 diabetes. However, after adjustment for age, sex, and baseline serum creatinine, there was no difference in ESKD or mortality risk by diabetes type.</p><p>By contrast, in a large registry of over one million patients, the incidence of ESKD was higher among type 1 compared with type 2 diabetes (1.9 versus 0.9 per 1000 person-years) [<a href="#rid65">65</a>]. The reasons why the rates of ESKD in this study were lower than in the previously mentioned study are unclear but may be due in part to a shorter diabetes duration at baseline.</p><p class="headingAnchor" id="H2497910842"><span class="h3">Youth-onset type 2 diabetes</span><span class="headingEndMark"> — </span>Although previously less recognized, type 2 diabetes among youth is common and is a result of the obesity pandemic [<a href="#rid66">66</a>]. Youth-onset type 2 diabetes appears to result in CKD complications earlier and with a more rapid rate of progression than in type 1 diabetes [<a href="#rid67">67-69</a>]. The SEARCH for Diabetes in Youth study, a longitudinal, cohort study of youth-onset type 1 and type 2 diabetes, found a higher prevalence of moderately increased albuminuria at eight years after diabetes diagnosis among participants with type 2 as compared with type 1 diabetes (20 versus 6 percent) [<a href="#rid70">70</a>]. Albuminuria was also more likely to progress and less likely to regress in those who had youth-onset type 2 as compared with type 1 diabetes. In another study, the incidence of ESKD at 16 years of diabetes duration was 2.3 percent among those with youth-onset type 2 diabetes (at a mean age of 30 years); by contrast, no individuals with youth-onset type 1 diabetes developed ESKD over the same follow-up period [<a href="#rid68">68</a>].</p><p>The more aggressive diabetic kidney disease course in youth-onset type 2 diabetes may be related to social determinants of health. African Americans, Hispanic individuals, and American Indians are disproportionately affected with youth-onset type 2 diabetes [<a href="#rid66">66</a>] and are at higher risk for diabetic kidney disease [<a href="#rid48">48,71,72</a>]. However, in the SEARCH study mentioned above, ancestry and ethnicity did not completely explain the difference in albuminuria between youth-onset type 2 and youth-onset type 1 diabetes [<a href="#rid67">67</a>]. (See <a class="local">'Ancestry/ethnicity'</a> below.)</p><p class="headingAnchor" id="H2838941229"><span class="h2">Risk factors for diabetic kidney disease</span><span class="headingEndMark"> — </span>Diabetic kidney disease is a complex disease with multiple phenotypes. (See  <a class="medical medical_review" href="/d/html/119881.html" rel="external">"Diabetic kidney disease: Manifestations, evaluation, and diagnosis"</a>.)</p><p>Given the heterogeneity of disease and distinct biological pathways at play at different stages of disease, it is not surprising that epidemiologic studies have not consistently identified risk factors for diabetic kidney disease. It is clear, however, that while there is a genetic predisposition for diabetic kidney disease, both modifiable and nonmodifiable environmental risk factors play an important role via direct tissue damage and indirect or epigenetic modification.</p><p class="headingAnchor" id="H4054241558"><span class="h3">Age</span><span class="headingEndMark"> — </span>Increasing age is directly related to the prevalence of diabetic kidney disease with decreased eGFR, rising from 8 percent in the 5<sup>th</sup> decade to 19 percent in the 6<sup>th</sup> decade and 35 percent in the 7<sup>th</sup> decade of life [<a href="#rid73">73</a>]. The incidence rate of diabetic ESKD is 142, 274, 368, and 329 cases per 100,000 among diabetic persons aged &lt;45, 45 to 64, 65 to 74, and ≥75 years, respectively [<a href="#rid74">74</a>]. This may be due to age-related senescence of the kidney, which can contribute to CKD of any cause [<a href="#rid75">75</a>], and which may explain a rise in the prevalence of normoalbuminuric (rather than albuminuric) diabetic kidney disease starting in the 5<sup>th</sup> decade [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/d/html/119881.html" rel="external">"Diabetic kidney disease: Manifestations, evaluation, and diagnosis", section on 'Nonalbuminuric diabetic kidney disease'</a>.)</p><p>However, the primary reason for increases in diabetic kidney disease prevalence with age is the typically indolent course of diabetic kidney damage, requiring decades of exposure to diabetes for progressive kidney disease to manifest.</p><p class="headingAnchor" id="H3026978176"><span class="h3">Ancestry/ethnicity</span><span class="headingEndMark"> — </span>Compared with White populations, African American, Hispanic American, and American Indian populations have higher rates of albuminuria, decreased eGFR, and ESKD [<a href="#rid48">48,77,78</a>]. The highest rates of ESKD were historically among American Indians; however, with public health interventions, rates have declined significantly in this population [<a href="#rid79">79</a>]. Incidence rates of diabetic ESKD among African Americans, Hispanic Americans, and White Americans are estimated at 409, 307, and 266 cases per 100,000 diabetic persons; although these rates may be declining among White patients, this does not appear to be the case in other populations and may actually be rising among the Mexican American population [<a href="#rid53">53,74</a>].</p><p class="headingAnchor" id="H1255858092"><span class="h3">Sex</span><span class="headingEndMark"> — </span>Males are more likely to develop CKD in diabetes and have significantly higher risk of progression from late-stage CKD to ESKD (hazard ratio [HR] 1.37, 95% CI 1.17-1.62) [<a href="#rid80">80,81</a>]. Differences in genetic architecture, sex hormones, body composition (eg, muscle mass), and lifestyle factors (eg, smoking, obesity, physical activity, and diet) have been proposed as possible mediators for different CKD risks in males and females with diabetes.</p><p class="headingAnchor" id="H658887821"><span class="h3">Low socioeconomic status</span><span class="headingEndMark"> — </span>The disparity in diabetic kidney disease among disadvantaged populations is explained in large part by social determinants of health. Albuminuria and decreased eGFR (&lt;60 mL/min/1.72 m<sup>2</sup>) is more common among individuals with lower education level, even after controlling for other social, demographic, and clinical factors [<a href="#rid82">82</a>]. After controlling for self-identified race, the incidence rate of ESKD in one study was 4.5-fold higher among populations in which more than 25 percent lived below the poverty level as compared with populations in which fewer than 5 percent lived below the poverty level [<a href="#rid83">83</a>]. Socioeconomic status in people with type 1 diabetes is also associated with pathogenic factors involved in diabetic kidney disease, including glomerular hyperfiltration and levels of various cytokines [<a href="#rid84">84</a>].</p><p>Mediators of the association between low socioeconomic status and diabetic kidney disease are numerous. Access to care is a substantial issue and results from barriers to health insurance coverage, financial constraints in out-of-pocket medical costs, lack of transportation to healthcare providers, decreased language and literacy skills, personal beliefs (eg, focus on living in the present rather than future, destiny is driven by fate), and distrust in medical providers [<a href="#rid85">85,86</a>]. At the community level, poorer neighborhoods are at greater risk of environmental exposures (lead paint or tainted water), have fewer healthy food options and open spaces for physical activity to mitigate obesity, are more likely to have unhealthy behaviors (smoking, alcohol, illicit drugs), and often have less access to health care.</p><p class="headingAnchor" id="H3854439479"><span class="h3">Obesity</span><span class="headingEndMark"> — </span>Even in the absence of diabetes, obesity may lead to secondary focal segmental glomerulosclerosis (FSGS), termed "obesity-related glomerulopathy (ORG)" [<a href="#rid87">87</a>]. Notably, approximately 40 percent of these patients without diabetes have features of diabetic kidney disease (mesangial expansion, glomerular basement membrane thickening, and nodular glomerulosclerosis) [<a href="#rid88">88</a>]. Obesity is a significant risk factor for type 2 diabetes and can often accompany type 1 diabetes [<a href="#rid89">89</a>]. As a result, ORG and diabetic kidney disease often coexist and share many clinical and pathogenic features such as glomerular hyperfiltration, progressive albuminuria, podocyte injury, and FSGS [<a href="#rid90">90</a>]. Obesity results in activation of the renin-angiotensin-aldosterone system (RAAS), causing increased sodium retention, activation of the sympathetic nervous system, and increased intraglomerular capillary pressure, exacerbating similar processes caused by diabetes and also resulting in glomerulosclerosis [<a href="#rid5">5</a>].</p><p>Visceral obesity has a greater association with incident and progressive diabetic kidney disease than general obesity [<a href="#rid91">91</a>], possibly due to increased adipocyte cytokine production. On the other hand, adiponectin production from adipocytes is reduced, resulting in reduced AMP-activated protein kinase (AMPK) activation and ultimately increased oxidative stress and podocyte injury [<a href="#rid92">92</a>]. There is also increased production of tumor necrosis factor (TNF)-alpha, interleukin 6 (IL-6), and leptin in obese individuals, which results in greater transforming growth factor (TGF)-beta production [<a href="#rid93">93,94</a>].</p><p class="headingAnchor" id="H1693805458"><span class="h3">Smoking</span><span class="headingEndMark"> — </span>Smoking can result in nodular sclerosis of the kidney that is similar to diabetic glomerulosclerosis irrespective of diabetes status. In addition, smoking triggers many of the same pathogenic pathways that are active in diabetic kidney disease, such as endothelial dysfunction, oxidative stress, and inflammation [<a href="#rid95">95</a>]. (See <a class="local">'Innate immunity, oxidative stress, and inflammation'</a> above.)</p><p>Studies of smoking and diabetic kidney disease have yielded conflicting results, likely due to different study designs and specific definitions of smoking and diabetic kidney disease, although the majority report a higher risk of kidney disease among smokers [<a href="#rid96">96-98</a>]. As an example, in a meta-analysis of nine cohorts and more than 200,000 individuals, cigarette smoking was modestly associated with diabetic kidney disease, defined as moderately or severely increased albuminuria or an eGFR &lt;60 mL/min/1.73 m<sup>2</sup> (HR 1.07, 95% CI 1.01-1.13) [<a href="#rid96">96</a>].</p><p class="headingAnchor" id="H1953901819"><span class="h3">Hyperglycemia</span><span class="headingEndMark"> — </span>There is overwhelming evidence that glycemic control impacts the risk for incident and progressive diabetic kidney disease [<a href="#rid99">99,100</a>]. In addition, restoration of normal glycemic control with pancreatic transplantation in patients with type 1 diabetes can improve kidney disease, including resolution of structural damage, in the long term [<a href="#rid101">101,102</a>]. (See  <a class="medical medical_review" href="/d/html/1751.html" rel="external">"Glycemic control and vascular complications in type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1760.html" rel="external">"Glycemic control and vascular complications in type 2 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/7313.html" rel="external">"Pancreas-kidney transplantation in diabetes mellitus: Benefits and complications"</a> and <a class="local">'Pathogenesis'</a> above.)</p><p>Observational studies of both type 1 and type 2 diabetes have demonstrated that lower HbA1c levels are associated with reversal of hyperfiltration [<a href="#rid24">24,25</a>], increased albuminuria regression [<a href="#rid103">103,104</a>], reductions in worsening albuminuria [<a href="#rid70">70,105,106</a>], rapid eGFR decline [<a href="#rid107">107,108</a>], and the development of stage 3 CKD [<a href="#rid109">109</a>]. Such improvements can be observed, even in later stages of diabetic kidney disease, including severely increased albuminuria (urine albumin-to-creatinine ratio ≥300 mg/g) [<a href="#rid109">109</a>] and eGFR &lt;60 mL/min/1.73 m<sup>2</sup> [<a href="#rid109">109</a>].</p><p>Glycemic targets in patients with diabetes are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1750.html" rel="external">"Overview of general medical care in nonpregnant adults with diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1796.html" rel="external">"Management of blood glucose in adults with type 1 diabetes mellitus", section on 'Glycemic targets'</a> and  <a class="medical medical_review" href="/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus", section on 'Treatment goals'</a>.)</p><p class="headingAnchor" id="H4167572105"><span class="h3">Hypertension</span><span class="headingEndMark"> — </span>Blood pressure control is important to the pathogenesis and progression of diabetic kidney disease. Similar to the effect of hyperglycemia, there is a linear relationship between blood pressure and the risk for adverse kidney outcomes [<a href="#rid110">110,111</a>]. A systolic blood pressure greater than 140 mmHg has consistently been found to increase the risk for the development of severely increased albuminuria and stage 3 CKD [<a href="#rid110">110</a>]. A full discussion of randomized trials targeting different blood pressures can be found separately. (See  <a class="medical medical_review" href="/d/html/3829.html" rel="external">"Treatment of hypertension in patients with diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H2038689664"><span class="h3">Genetic factors</span><span class="headingEndMark"> — </span>Environmental factors may explain some of the disparities in diabetic kidney disease among African American, Hispanic American, and American Indian populations [<a href="#rid112">112</a>]. Familial clustering of diabetic kidney disease and diabetic ESKD has long been recognized [<a href="#rid113">113</a>], with heritability estimates ranging from 0.30 to 0.75 depending upon the population (eg, ancestry, ethnicity, diabetes type) and trait under study (eg, albuminuria, eGFR, ESKD) [<a href="#rid114">114</a>].</p><p>The quest to identify specific genetic etiologies of diabetic kidney disease has been challenging. Several candidate genes were initially implicated in the susceptibility and progression of diabetic kidney disease, but subsequent studies failed to replicate the findings [<a href="#rid115">115</a>]. Several large genome-wide association studies identified genes and gene regions for various diabetic kidney disease phenotypes in both type 1 and type 2 diabetes [<a href="#rid116">116-119</a>]; however, consistent associations for only a few loci were replicated in subsequent studies. </p><p>Complex conditions, particularly "diseases within diseases," like development of kidney disease in diabetes, present major challenges for deciphering genetic associations [<a href="#rid120">120,121</a>]. However, genome-wide association studies using large data sets have yielded insights about genetic predisposition to diabetic kidney disease. As an example, one variant in the <em>Col4A3</em> gene (the same gene associated with Alport syndrome) was associated with protection from clinical diabetic kidney disease in individuals with type 1 diabetes; in the subset who underwent kidney biopsy, this variant was also associated with less severe glomerular pathology. Variants in other genes related to collagen pathophysiology and kidney fibrosis (<em>DDR1, COLEC11, BMP7</em>) are, similarly, associated with various phenotypes of diabetic kidney disease.</p><p>The apolipoprotein 1 (<em>APOL1</em>) gene explains much of the disparity in nondiabetic ESKD among Black individuals but has not born out as a causative factor for diabetic kidney disease [<a href="#rid122">122</a>]. However, APOL1 variants are associated with an increased risk for progression of diabetic kidney disease in Black patients. (See  <a class="medical medical_review" href="/d/html/7236.html" rel="external">"Epidemiology of chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H1434476229"><span class="h3">Acute kidney injury</span><span class="headingEndMark"> — </span>Diabetes, particularly if accompanied by diabetic kidney disease, is a risk factor for various types of acute kidney injury (AKI) [<a href="#rid123">123,124</a>]. Conversely, AKI is increasingly recognized as a risk factor for CKD due to maladaptive repair processes that become chronic. In diabetic kidney disease, these AKI-induced injuries involve the podocyte and endothelium of the glomerulus and induce myofibroblast transformation of tubular cells. As a result, both the glomerulopathy and tubulointerstitial fibrosis associated with diabetic kidney disease may be accelerated by AKI.</p><p class="headingAnchor" id="H1040245218"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/140971.html" rel="external">"Society guideline links: Diabetic kidney disease"</a>.)</p><p class="headingAnchor" id="H106470905"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4428.html" rel="external">"Patient education: Diabetic kidney disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1108077258"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Diabetic kidney disease is a complex and heterogeneous disease with numerous overlapping etiologic pathways. Hyperglycemia results in production of advanced glycation end-products (AGE) and reactive oxygen species. While hyperglycemia undoubtedly plays a central role, hyperinsulinemia and insulin resistance also may incite pathogenic mechanisms, possibly accounting for variation in histopathology between type 1 and type 2 diabetes. Ultimately, alterations in glomerular hemodynamics, inflammation, and fibrosis are primary mediators of kidney tissue damage  (<a class="graphic graphic_figure graphicRef122590" href="/d/graphic/122590.html" rel="external">figure 1</a>), although the relative contribution of these mechanisms likely varies between individuals and over the course of the natural history of diabetic kidney disease. (See <a class="local">'Glomerular hemodynamics'</a> above and <a class="local">'Innate immunity, oxidative stress, and inflammation'</a> above and <a class="local">'Interstitial fibrosis and tubular atrophy (IFTA)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Diabetes is the leading cause of chronic kidney disease (CKD) in the United States and worldwide. The proportion of people with diabetes who also have CKD has remained relatively stable (approximately 25 to 30 percent), although the distribution of clinical manifestations of diabetic kidney disease has changed. The prevalence of persistent albuminuria is declining, but the prevalence of decreased estimated glomerular filtration rate (eGFR) is rising. (See <a class="local">'Incidence and prevalence'</a> above.)</p><p></p><p class="bulletIndent1">It is unclear whether the natural history and rate of progression of diabetic kidney disease differs according to diabetes type. In the vast majority of people with type 2 diabetes, disease onset is after the age of 40 years, and other factors such as age-related senescence of the kidney and hypertension can participate in kidney function decline to varying degrees. In addition, type 2 diabetes can be asymptomatic for years, resulting in a delay in diagnosis; therefore, the true time of onset of the hyperglycemic exposure is usually unknown. (See <a class="local">'Type 1 versus type 2 diabetes'</a> above.)</p><p></p><p class="bulletIndent1">Type 2 diabetes among youth is common and another result of the obesity pandemic. Youth-onset type 2 diabetes appears to result in CKD complications earlier and with a more rapid rate of progression than with youth-onset type 1 diabetes. (See <a class="local">'Youth-onset type 2 diabetes'</a> above.)</p><p></p><p class="bulletIndent1">Among patients with diabetes, risk factors for diabetic kidney disease include older age, African American or American Indian ancestry, Hispanic ethnicity, low socioeconomic status, obesity, smoking, poor glycemic and blood pressure control, and genetic factors. (See <a class="local">'Risk factors for diabetic kidney disease'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vallon V, Komers R. Pathophysiology of the diabetic kidney. Compr Physiol 2011; 1:1175.</a></li><li><a class="nounderline abstract_t">Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288:2579.</a></li><li><a class="nounderline abstract_t">Pichler R, Afkarian M, Dieter BP, Tuttle KR. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. Am J Physiol Renal Physiol 2017; 312:F716.</a></li><li><a class="nounderline abstract_t">Schelling JR. The Contribution of Lipotoxicity to Diabetic Kidney Disease. Cells 2022; 11.</a></li><li><a class="nounderline abstract_t">Hostetter TH. Hyperfiltration and glomerulosclerosis. Semin Nephrol 2003; 23:194.</a></li><li><a class="nounderline abstract_t">Tonneijck L, Muskiet MH, Smits MM, et al. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. J Am Soc Nephrol 2017; 28:1023.</a></li><li><a class="nounderline abstract_t">Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 2012; 8:293.</a></li><li><a class="nounderline abstract_t">Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49:1774.</a></li><li><a class="nounderline abstract_t">Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380:2295.</a></li><li><a class="nounderline abstract_t">Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380:347.</a></li><li><a class="nounderline abstract_t">The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388:117.</a></li><li><a class="nounderline abstract_t">van Bommel EJM, Lytvyn Y, Perkins BA, et al. Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function. Kidney Int 2020; 97:631.</a></li><li><a class="nounderline abstract_t">Dekkers CCJ, Wheeler DC, Sjöström CD, et al. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. Nephrol Dial Transplant 2018; 33:2005.</a></li><li><a class="nounderline abstract_t">Bakris GL. Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors. Am J Kidney Dis 2019; 74:573.</a></li><li><a class="nounderline abstract_t">Kraus BJ, Weir MR, Bakris GL, et al. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int 2021; 99:750.</a></li><li><a class="nounderline abstract_t">Heerspink HJL, Cherney DZI. Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation. Clin J Am Soc Nephrol 2021; 16:1278.</a></li><li><a class="nounderline abstract_t">Hill JV, Findon G, Appelhoff RJ, Endre ZH. Renal autoregulation and passive pressure-flow relationships in diabetes and hypertension. Am J Physiol Renal Physiol 2010; 299:F837.</a></li><li><a class="nounderline abstract_t">Hostetter TH. Diabetic nephropathy. Metabolic versus hemodynamic considerations. Diabetes Care 1992; 15:1205.</a></li><li><a class="nounderline abstract_t">Denic A, Mathew J, Lerman LO, et al. Single-Nephron Glomerular Filtration Rate in Healthy Adults. N Engl J Med 2017; 376:2349.</a></li><li><a class="nounderline abstract_t">Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med 2021; 385:1737.</a></li><li><a class="nounderline abstract_t">Hoy WE, Douglas-Denton RN, Hughson MD, et al. A stereological study of glomerular number and volume: preliminary findings in a multiracial study of kidneys at autopsy. Kidney Int Suppl 2003; :S31.</a></li><li><a class="nounderline abstract_t">Kwong YT, Stevens LA, Selvin E, et al. Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations. Am J Kidney Dis 2010; 56:39.</a></li><li><a class="nounderline abstract_t">Cherney DZ, Sochett EB, Dekker MG, Perkins BA. Ability of cystatin C to detect acute changes in glomerular filtration rate provoked by hyperglycaemia in uncomplicated Type 1 diabetes. Diabet Med 2010; 27:1358.</a></li><li><a class="nounderline abstract_t">Tuttle KR, Bruton JL, Perusek MC, et al. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 1991; 324:1626.</a></li><li><a class="nounderline abstract_t">Tuttle KR, Bruton JL. Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. Kidney Int 1992; 42:167.</a></li><li><a class="nounderline abstract_t">Magee GM, Bilous RW, Cardwell CR, et al. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009; 52:691.</a></li><li><a class="nounderline abstract_t">Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012; 35:2061.</a></li><li><a class="nounderline abstract_t">Bjornstad P, Cherney DZ, Snell-Bergeon JK, et al. Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with Type 1 diabetes. Nephrol Dial Transplant 2015; 30:1706.</a></li><li><a class="nounderline abstract_t">Ibrahim HN, Rosenberg ME, Hostetter TH. Role of the renin-angiotensin-aldosterone system in the progression of renal disease: a critical review. Semin Nephrol 1997; 17:431.</a></li><li><a class="nounderline abstract_t">Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 2018; 94:26.</a></li><li><a class="nounderline abstract_t">Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005; 83:876.</a></li><li><a class="nounderline abstract_t">Tang SCW, Yiu WH. Innate immunity in diabetic kidney disease. Nat Rev Nephrol 2020; 16:206.</a></li><li><a class="nounderline abstract_t">Hojs R, Ekart R, Bevc S, Hojs N. Markers of Inflammation and Oxidative Stress in the Development and Progression of Renal Disease in Diabetic Patients. Nephron 2016; 133:159.</a></li><li><a class="nounderline abstract_t">Tuttle KR, Agarwal R, Alpers CE, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int 2022; 102:248.</a></li><li><a class="nounderline abstract_t">Nguyen D, Ping F, Mu W, et al. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton) 2006; 11:226.</a></li><li><a class="nounderline abstract_t">Tesch GH. Macrophages and diabetic nephropathy. Semin Nephrol 2010; 30:290.</a></li><li><a class="nounderline abstract_t">Humphreys BD, Xu F, Sabbisetti V, et al. Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest 2013; 123:4023.</a></li><li><a class="nounderline abstract_t">Awad AS, You H, Gao T, et al. Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury. Kidney Int 2015; 88:722.</a></li><li><a class="nounderline abstract_t">Border WA, Brees D, Noble NA. Transforming growth factor-beta and extracellular matrix deposition in the kidney. Contrib Nephrol 1994; 107:140.</a></li><li><a class="nounderline abstract_t">Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000; 97:8015.</a></li><li><a class="nounderline abstract_t">Riser BL, Denichilo M, Cortes P, et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 2000; 11:25.</a></li><li><a class="nounderline abstract_t">Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48:2229.</a></li><li><a class="nounderline abstract_t">Nakagawa T, Sato W, Kosugi T, Johnson RJ. Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy. J Diabetes Res 2013; 2013:184539.</a></li><li><a class="nounderline abstract_t">Gnudi L. Angiopoietins and diabetic nephropathy. Diabetologia 2016; 59:1616.</a></li><li><a class="nounderline abstract_t">An Y, Xu F, Le W, et al. Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant 2015; 30:257.</a></li><li><a class="nounderline abstract_t">Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54:1615.</a></li><li><a class="nounderline abstract_t">Bonventre JV. Can we target tubular damage to prevent renal function decline in diabetes? Semin Nephrol 2012; 32:452.</a></li><li class="breakAll">United States Renal Data System. USRDS 2018 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, editor, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2017.</li><li class="breakAll">International Diabetes Federation. IDF Diabetes Atlas. International Diabetes Federation, editor, Brussels, Belgium 2017.</li><li><a class="nounderline abstract_t">Wyld MLR, Morton RL, Aouad L, et al. The impact of comorbid chronic kidney disease and diabetes on health-related quality-of-life: a 12-year community cohort study. Nephrol Dial Transplant 2021; 36:1048.</a></li><li><a class="nounderline abstract_t">Li H, Lu W, Wang A, et al. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017. J Diabetes Investig 2021; 12:346.</a></li><li><a class="nounderline abstract_t">Nichols GA, Ustyugova A, Déruaz-Luyet A, et al. Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure. J Am Soc Nephrol 2020; 31:1594.</a></li><li><a class="nounderline abstract_t">Afkarian M, Zelnick LR, Hall YN, et al. Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. JAMA 2016; 316:602.</a></li><li><a class="nounderline abstract_t">Duru OK, Middleton T, Tewari MK, Norris K. The Landscape of Diabetic Kidney Disease in the United States. Curr Diab Rep 2018; 18:14.</a></li><li><a class="nounderline abstract_t">Chu CD, McCulloch CE, Banerjee T, et al. CKD Awareness Among US Adults by Future Risk of Kidney Failure. Am J Kidney Dis 2020; 76:174.</a></li><li><a class="nounderline abstract_t">Burrows NR, Koyama A, Pavkov ME. Reported Cases of End-Stage Kidney Disease - United States, 2000-2019. MMWR Morb Mortal Wkly Rep 2022; 71:412.</a></li><li><a class="nounderline abstract_t">Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013; 24:302.</a></li><li><a class="nounderline abstract_t">Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380:1662.</a></li><li><a class="nounderline abstract_t">Tuttle KR, Wong L, St Peter W, et al. Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clin J Am Soc Nephrol 2022; 17:1092.</a></li><li><a class="nounderline abstract_t">Cheng HT, Xu X, Lim PS, Hung KY. Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000-2015. Diabetes Care 2021; 44:89.</a></li><li><a class="nounderline abstract_t">Koye DN, Shaw JE, Reid CM, et al. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. Diabet Med 2017; 34:887.</a></li><li><a class="nounderline abstract_t">Hill CJ, Cardwell CR, Patterson CC, et al. Chronic kidney disease and diabetes in the national health service: a cross-sectional survey of the U.K. national diabetes audit. Diabet Med 2014; 31:448.</a></li><li><a class="nounderline abstract_t">Cusick M, Chew EY, Hoogwerf B, et al. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int 2004; 66:1173.</a></li><li><a class="nounderline abstract_t">Hadjadj S, Cariou B, Fumeron F, et al. Death, end-stage renal disease and renal function decline  in patients with diabetic nephropathy in French cohorts of type 1  and type 2 diabetes. Diabetologia 2016; 59:208.</a></li><li><a class="nounderline abstract_t">Koye DN, Magliano DJ, Reid CM, et al. Trends in Incidence of ESKD in People With Type 1 and Type 2 Diabetes in Australia, 2002-2013. Am J Kidney Dis 2019; 73:300.</a></li><li><a class="nounderline abstract_t">Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012. N Engl J Med 2017; 376:1419.</a></li><li><a class="nounderline abstract_t">Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. JAMA 2017; 317:825.</a></li><li><a class="nounderline abstract_t">Dart AB, Sellers EA, Martens PJ, et al. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care 2012; 35:1265.</a></li><li><a class="nounderline abstract_t">Krakoff J, Lindsay RS, Looker HC, et al. Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes. Diabetes Care 2003; 26:76.</a></li><li><a class="nounderline abstract_t">Kahkoska AR, Isom S, Divers J, et al. The early natural history of albuminuria in young adults with youth-onset type 1 and type 2 diabetes. J Diabetes Complications 2018; 32:1160.</a></li><li><a class="nounderline abstract_t">Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 2003; 14:2902.</a></li><li><a class="nounderline abstract_t">Derose SF, Rutkowski MP, Crooks PW, et al. Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system. Am J Kidney Dis 2013; 62:236.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System - United States 2018 [June 19, 2019]. Available from: http://www.cdc.gov/ckd.</li><li><a class="nounderline abstract_t">Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care 2010; 33:73.</a></li><li><a class="nounderline abstract_t">Denic A, Glassock RJ, Rule AD. Structural and Functional Changes With the Aging Kidney. Adv Chronic Kidney Dis 2016; 23:19.</a></li><li><a class="nounderline abstract_t">Mottl AK, Kwon KS, Mauer M, et al. Normoalbuminuric diabetic kidney disease in the U.S. population. J Diabetes Complications 2013; 27:123.</a></li><li><a class="nounderline abstract_t">Bryson CL, Ross HJ, Boyko EJ, Young BA. Racial and ethnic variations in albuminuria in the US Third National Health and Nutrition Examination Survey (NHANES III) population: associations with diabetes and level of CKD. Am J Kidney Dis 2006; 48:720.</a></li><li><a class="nounderline abstract_t">Narres M, Claessen H, Droste S, et al. The Incidence of End-Stage Renal Disease in the Diabetic (Compared to the Non-Diabetic) Population: A Systematic Review. PLoS One 2016; 11:e0147329.</a></li><li><a class="nounderline abstract_t">Pavkov ME, Knowler WC, Bennett PH, et al. Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians. Kidney Int 2006; 70:1840.</a></li><li><a class="nounderline abstract_t">Tuttle KR, Jones CR, Daratha KB, et al. Incidence of Chronic Kidney Disease among Adults with Diabetes, 2015-2020. N Engl J Med 2022; 387:1430.</a></li><li><a class="nounderline abstract_t">Tsai WC, Wu HY, Peng YS, et al. Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis. Medicine (Baltimore) 2016; 95:e3013.</a></li><li><a class="nounderline abstract_t">Choi AI, Weekley CC, Chen SC, et al. Association of educational attainment with chronic disease and mortality: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2011; 58:228.</a></li><li><a class="nounderline abstract_t">Volkova N, McClellan W, Klein M, et al. Neighborhood poverty and racial differences in ESRD incidence. J Am Soc Nephrol 2008; 19:356.</a></li><li><a class="nounderline abstract_t">Cummings LAM, Clarke A, Sochett E, et al. Social Determinants of Health Are Associated with Markers of Renal Injury in Adolescents with Type 1 Diabetes. J Pediatr 2018; 198:247.</a></li><li><a class="nounderline abstract_t">McClellan WM, Casey MT, Hughley J, Freund E. Population-based interventions to reduce socioeconomic disparities in chronic kidney disease. Semin Nephrol 2010; 30:33.</a></li><li><a class="nounderline abstract_t">Nicholas SB, Kalantar-Zadeh K, Norris KC. Socioeconomic disparities in chronic kidney disease. Adv Chronic Kidney Dis 2015; 22:6.</a></li><li><a class="nounderline abstract_t">D'Agati VD, Chagnac A, de Vries AP, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol 2016; 12:453.</a></li><li><a class="nounderline abstract_t">Choung HG, Bomback AS, Stokes MB, et al. The spectrum of kidney biopsy findings in patients with morbid obesity. Kidney Int 2019; 95:647.</a></li><li><a class="nounderline abstract_t">Corbin KD, Driscoll KA, Pratley RE, et al. Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. Endocr Rev 2018; 39:629.</a></li><li><a class="nounderline abstract_t">Bayliss G, Weinrauch LA, D'Elia JA. Pathophysiology of obesity-related renal dysfunction contributes to diabetic nephropathy. Curr Diab Rep 2012; 12:440.</a></li><li><a class="nounderline abstract_t">Hu J, Yang S, Zhang A, et al. Abdominal Obesity Is More Closely Associated With Diabetic Kidney Disease Than General Obesity. Diabetes Care 2016; 39:e179.</a></li><li><a class="nounderline abstract_t">Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118:1645.</a></li><li><a class="nounderline abstract_t">Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol 2006; 151:175.</a></li><li><a class="nounderline abstract_t">Aroor AR, McKarns S, Demarco VG, et al. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism 2013; 62:1543.</a></li><li><a class="nounderline abstract_t">Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 2014; 34:509.</a></li><li><a class="nounderline abstract_t">Liao D, Ma L, Liu J, Fu P. Cigarette smoking as a risk factor for diabetic nephropathy: A systematic review and meta-analysis of prospective cohort studies. PLoS One 2019; 14:e0210213.</a></li><li><a class="nounderline abstract_t">Feodoroff M, Harjutsalo V, Forsblom C, et al. Smoking and progression of diabetic nephropathy in patients with type 1 diabetes. Acta Diabetol 2016; 53:525.</a></li><li><a class="nounderline abstract_t">Zitt E, Pscheidt C, Concin H, et al. Anthropometric and Metabolic Risk Factors for ESRD Are Disease-Specific: Results from a Large Population-Based Cohort Study in Austria. PLoS One 2016; 11:e0161376.</a></li><li><a class="nounderline abstract_t">Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977.</a></li><li><a class="nounderline abstract_t">Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405.</a></li><li><a class="nounderline abstract_t">Fioretto P, Sutherland DE, Najafian B, Mauer M. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2006; 69:907.</a></li><li><a class="nounderline abstract_t">Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339:69.</a></li><li><a class="nounderline abstract_t">Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348:2285.</a></li><li><a class="nounderline abstract_t">Gaede P, Tarnow L, Vedel P, et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004; 19:2784.</a></li><li><a class="nounderline abstract_t">de Boer IH, Rue TC, Cleary PA, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011; 171:412.</a></li><li><a class="nounderline abstract_t">Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55:1832.</a></li><li><a class="nounderline abstract_t">Skupien J, Warram JH, Smiles AM, et al. The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int 2012; 82:589.</a></li><li><a class="nounderline abstract_t">Zoppini G, Targher G, Chonchol M, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol 2012; 7:401.</a></li><li><a class="nounderline abstract_t">de Boer IH, Afkarian M, Rue TC, et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2014; 25:2342.</a></li><li><a class="nounderline abstract_t">Ku E, McCulloch CE, Mauer M, et al. Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes. Diabetes Care 2016; 39:2218.</a></li><li><a class="nounderline abstract_t">Rossing K, Christensen PK, Hovind P, et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004; 66:1596.</a></li><li><a class="nounderline abstract_t">Lipworth L, Mumma MT, Cavanaugh KL, et al. Incidence and predictors of end stage renal disease among low-income blacks and whites. PLoS One 2012; 7:e48407.</a></li><li><a class="nounderline abstract_t">Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320:1161.</a></li><li><a class="nounderline abstract_t">Satko SG, Sedor JR, Iyengar SK, Freedman BI. Familial clustering of chronic kidney disease. Semin Dial 2007; 20:229.</a></li><li><a class="nounderline abstract_t">Williams WW, Salem RM, McKnight AJ, et al. Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy. Diabetes 2012; 61:2187.</a></li><li><a class="nounderline abstract_t">Guan M, Keaton JM, Dimitrov L, et al. Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans. Hum Genomics 2019; 13:21.</a></li><li><a class="nounderline abstract_t">Iyengar SK, Sedor JR, Freedman BI, et al. Genome-Wide Association and Trans-ethnic Meta-Analysis for Advanced Diabetic Kidney Disease: Family Investigation of Nephropathy and Diabetes (FIND). PLoS Genet 2015; 11:e1005352.</a></li><li><a class="nounderline abstract_t">Sandholm N, Salem RM, McKnight AJ, et al. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 2012; 8:e1002921.</a></li><li><a class="nounderline abstract_t">van Zuydam NR, Ahlqvist E, Sandholm N, et al. A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes 2018; 67:1414.</a></li><li><a class="nounderline abstract_t">Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol 2020; 16:377.</a></li><li><a class="nounderline abstract_t">Salem RM, Todd JN, Sandholm N, et al. Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. J Am Soc Nephrol 2019; 30:2000.</a></li><li><a class="nounderline abstract_t">Kruzel-Davila E, Wasser WG, Aviram S, Skorecki K. APOL1 nephropathy: from gene to mechanisms of kidney injury. Nephrol Dial Transplant 2016; 31:349.</a></li><li><a class="nounderline abstract_t">Zuk A, Bonventre JV. Recent advances in acute kidney injury and its consequences and impact on chronic kidney disease. Curr Opin Nephrol Hypertens 2019; 28:397.</a></li><li><a class="nounderline abstract_t">Yu SM, Bonventre JV. Acute Kidney Injury and Progression of Diabetic Kidney Disease. Adv Chronic Kidney Dis 2018; 25:166.</a></li></ol></div><div id="topicVersionRevision">Topic 3103 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23733640" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pathophysiology of the diabetic kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12444865" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Molecular understanding of hyperglycemia's adverse effects for diabetic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27558558" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36291104" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Contribution of Lipotoxicity to Diabetic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12704579" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hyperfiltration and glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28143897" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22349487" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Glomerular hyperfiltration: definitions, mechanisms and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8743495" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The hyperfiltration theory: a paradigm shift in nephrology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30990260" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415602" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36331190" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Empagliflozin in Patients with Chronic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32200854" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370424" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31262591" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33181154" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33879500" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660017" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Renal autoregulation and passive pressure-flow relationships in diabetes and hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1396017" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diabetic nephropathy. Metabolic versus hemodynamic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28614683" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Single-Nephron Glomerular Filtration Rate in Healthy Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34554658" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12864872" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A stereological study of glomerular number and volume: preliminary findings in a multiracial study of kidneys at autopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20537455" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21059087" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ability of cystatin C to detect acute changes in glomerular filtration rate provoked by hyperglycaemia in uncomplicated Type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2030719" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1635346" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19198800" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22773704" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Glomerular hyperfiltration and renal disease progression in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26050268" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with Type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9316211" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Role of the renin-angiotensin-aldosterone system in the progression of renal disease: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29735306" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16133426" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Understanding RAGE, the receptor for advanced glycation end products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31942046" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Innate immunity in diabetic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27344598" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Markers of Inflammation and Oxidative Stress in the Development and Progression of Renal Disease in Diabetic Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35661785" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Molecular mechanisms and therapeutic targets for diabetic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16756636" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Macrophage accumulation in human progressive diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20620673" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Macrophages and diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23979159" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26061548" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Macrophage-derived tumor necrosis factor-αmediates diabetic renal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8004960" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Transforming growth factor-beta and extracellular matrix deposition in the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10859350" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10616837" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10535459" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24386643" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27207083" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Angiopoietins and diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25063425" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Renal histologic changes and the outcome in patients with diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15919781" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The pathobiology of diabetic complications: a unifying mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23062986" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Can we target tubular damage to prevent renal function decline in diabetes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23062986" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Can we target tubular damage to prevent renal function decline in diabetes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23062986" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Can we target tubular damage to prevent renal function decline in diabetes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32170940" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The impact of comorbid chronic kidney disease and diabetes on health-related quality-of-life: a 12-year community cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32654341" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32487562" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27532915" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29457196" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The Landscape of Diabetic Kidney Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32305206" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : CKD Awareness Among US Adults by Future Risk of Kidney Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35298452" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Reported Cases of End-Stage Kidney Disease - United States, 2000-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23362314" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Kidney disease and increased mortality risk in type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23013602" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35649722" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33203706" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28164387" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24102856" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chronic kidney disease and diabetes in the national health service: a cross-sectional survey of the U.K. national diabetes audit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327414" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26486355" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Death, end-stage renal disease and renal function decline  in patients with diabetic nephropathy in French cohorts of type 1  and type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30579709" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Trends in Incidence of ESKD in People With Type 1 and Type 2 Diabetes in Australia, 2002-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28402773" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28245334" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22432116" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : High burden of kidney disease in youth-onset type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12502661" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30316542" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The early natural history of albuminuria in young adults with youth-onset type 1 and type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14569100" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23499049" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23499049" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Racial differences in estimated GFR decline, ESRD, and mortality in an integrated health system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20040673" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26709059" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Structural and Functional Changes With the Aging Kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23182925" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Normoalbuminuric diabetic kidney disease in the U.S. population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17059991" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Racial and ethnic variations in albuminuria in the US Third National Health and Nutrition Examination Survey (NHANES III) population: associations with diabetes and level of CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26812415" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The Incidence of End-Stage Renal Disease in the Diabetic (Compared to the Non-Diabetic) Population: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17003816" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36239650" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Incidence of Chronic Kidney Disease among Adults with Diabetes, 2015-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26986114" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21601328" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Association of educational attainment with chronic disease and mortality: the Kidney Early Evaluation Program (KEEP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057219" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Neighborhood poverty and racial differences in ESRD incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29752172" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Social Determinants of Health Are Associated with Markers of Renal Injury in Adolescents with Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20116646" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Population-based interventions to reduce socioeconomic disparities in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25573507" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Socioeconomic disparities in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27263398" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30712921" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The spectrum of kidney biopsy findings in patients with morbid obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30060120" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22638939" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pathophysiology of obesity-related renal dysfunction contributes to diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27538755" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Abdominal Obesity Is More Closely Associated With Diabetic Kidney Disease Than General Obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18431508" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Adiponectin regulates albuminuria and podocyte function in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16929141" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Leptin and renal fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23932846" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24554606" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30716100" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Cigarette smoking as a risk factor for diabetic nephropathy: A systematic review and meta-analysis of prospective cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26668013" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Smoking and progression of diabetic nephropathy in patients with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27537361" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Anthropometric and Metabolic Risk Factors for ESRD Are Disease-Specific: Results from a Large Population-Based Cohort Study in Austria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8366922" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10938048" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16518350" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9654536" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Reversal of lesions of diabetic nephropathy after pancreas transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12788992" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Regression of microalbuminuria in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15328385" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21403038" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16731850" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22622493" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22282481" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24925722" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Renal outcomes in patients with type 1 diabetes and macroalbuminuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27872156" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15458456" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Progression of nephropathy in type 2 diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23110237" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Incidence and predictors of end stage renal disease among low-income blacks and whites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2710189" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17555489" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Familial clustering of chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22721967" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31092297" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26305897" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Genome-Wide Association and Trans-ethnic Meta-Analysis for Advanced Diabetic Kidney Disease: Family Investigation of Nephropathy and Diabetes (FIND).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23028342" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : New susceptibility loci associated with kidney disease in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29703844" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32398868" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Genetics of diabetes mellitus and diabetes complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31537649" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25561578" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : APOL1 nephropathy: from gene to mechanisms of kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30925515" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Recent advances in acute kidney injury and its consequences and impact on chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29580581" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Acute Kidney Injury and Progression of Diabetic Kidney Disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
